Su tratamentu pro su tumore a sos prumones dipendet dae medas fatores, intre sos cales s'istàdiu de su tumore, su tipu de tumore a sos prumones e sa salude generale de su malàidu.
Unas cantas optziones de tratamentu comunas includint:
1. Chirurgia: custu est a s'ispissu su tratamentu prefèridu pro su tumore a su purmones in fase primidia.
Su dutore est serradu, boghende su tumore e una parte pitica de tessidu sanu a inghìriu.
2. Radioterapia: sa radiatzione a energia arta est impreada pro ochire sas tzèllulas tumorales e fàghere minimare sos tumores.
Si podet impreare a sa sola o in cumbinatzione cun àteros tratamentos.
3. Cimioterapia: Custu tratamentu usat meighinas pro ochìere sas tzèllulas tumorales.
Si podet dare pro via endovenosa o orale, e a s'ispissu s'usat in cumbinatzione cun àteros tratamentos.
4. Teràpia mirada: Custa terapia tirat a genes o proteinas ispetzìficos chi contribuint a sa crèschida e sa subravivèntzia de sas tzèllulas tumorales.
A s'ispissu est impreadu pro su tumore a sos purmones avantzadu o metastàticu.
5. Immunoterapia: custu tratamentu agiudat su sistema immunitàriu a reconnòschere e atacare sas tzèllulas tumorales.
A s'ispissu est impreadu pro su tumore a sos purmones avantzadu o metastàticu.
6. Terapia fotodinàmica: Custu tratamentu usat una meighina ativada dae sa lughe pro ochìere sas tzèllulas tumorales.
A s'ispissu est impreadu pro su crancu a su purmones in fase primidia.
7. Proton therapy: Custa est una genia de radioterapia chi impreat protones imbetzes de rajos X pro fornire radiatziones a su tumore.
A s'ispissu est impreadu pro su crancu a su purmones in fase primidia.
8. Isperimentatziones clìnicas: sos malàidos podent èssere idòneos a partetzipare a sas proas clìnicas pro testare tratamentos noos o cumbinatziones de tratamentos.
Est de importu a discùtere sas mègius opziones de tratamentu cun un'iscuadra sanitària, ca su pranu de tratamentu prus eficatze at a dipèndere dae sa situatzione ispetzìfica de su sogetu.
Chen JH, Wu J, Xu Q: The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. , 4 (): 61.
Furuse K: [Photodynamic therapy of centrally located early-stage lung cancer]. Gan To Kagaku Ryoho. 1996, 23 (1): 27-30.
Gálffy G: [From rare mutations to classical ones, inhibition of signaling pathways in non-small cell lung cancer]. Magy Onkol. 2020, 64 (3): 196-204.
Magalhães M, Alvarez-Lorenzo C, Concheiro A, Figueiras A, Santos AC, Veiga F: RNAi-based therapeutics for lung cancer: biomarkers, microRNAs, and nanocarriers. Expert Opin Drug Deliv. 2018, 15 (10): 965-982.
Kataoka M, Fujiwara T, Tanaka N: [Gene therapy for lung cancer]. Nihon Geka Gakkai Zasshi. 2002, 103 (2): 244-9.
Jin C, Yang B: A Case of Delayed Diagnostic Pulmonary Tuberculosis during Targeted Therapy in an EGFR Mutant Non-Small Cell Lung Cancer Patient. Case Rep Oncol. , 14 (1): 659-663.
Wang Y, Liu Q, Chen H, You J, Peng B, Cao F, Zhang X, Chen Q, Uzan G, Xu L, Zhang D: Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance. Anticancer Drugs. 2018, 29 (8): 748-755.
['Disclaimer: mèdicu']
['Custu giassu est fatu po istudiare e informae sa zente e non est unu giassu de consultatzione o de azudu.']
['Sa informassione frunida no est de impreare pro diagnosticare o curare unu problema de salude o una maladia, e sos chi chircant consìgios mèdicos personales si depent cuntatare cun unu mèdicu autorizadu.']
["S'arricordaus ca sa retza neurali chi creat rispostas a is pregontas est imperfeta candu si chistionat de nùmerus, po nai su nùmeru de personas chi tenint una maladia."]
["Chirca semper su parre de su dotore tuo o de un'àteru dotore cualificadu pro cale si siat cunditzione mèiga. No disconnoscas mai su parre de unu professionista mèigu o non bi tardes a l'agatare pro carchi cosa chi as lèghidu in custu situ. Si tenes pensamentos de tènnere un'emergèntzia mèiga, telefona a su 911 o bae a su pronto soccorsu prus acanta."]
['Disclaimer: deretu de autore']
['Sa Digital Millennium Copyright Act de su 1998, 17 U.S.C. § 512 (sa DMCA) donat unu recursu a is propietàrius de deretus de autori chi pensant chi unu materiali chi aparit in Internet ofendet is deretus insoru assuta de sa lei de su deretu de autori de is IUA. ']
["Si creis de bona fidi chi calicunu cuntènniu o materiale postu a disponimentu in su giassu o in is servìtzios nostros at ofesu is deretus de autore tuos, tui (o s'agenti tuo) nos podes imbiare una comunicatzioni domandendi de nde bogare su cuntènniu o su materiale, o de nde blocare s'atzessu."]
['Sos annùntzios depent èssere imbiados pro iscrittu pro mèdiu de posta eletrònica (càstia sa setzione "Cuntatu" pro s\'indiritzu de posta eletrònica). ']
["Sa DMCA recheret chi sa notìfica tua de sa presunta violatzione de copyright incluat sas informatziones sighentes: (1) descritzione de s'òpera amparada dae copyright chi est ogetu de sa presunta violatzione; (2) descritzione de su chi si narat chi est unu cuntènnidu chi diat pòdere èssere istadu violadu e informatziones bastantes pro nos permìtere de localizare su cuntènnidu; (3) informatziones pro ti cuntatare, intre cales s'indiritzu tuo, su nùmeru de telèfono e s'indiritzu de posta eletrònica; (4) una decraratzione tua pro nàrrere chi tenes bona fide chi su cuntènnidu de sa manera chi ses lamentende non est autorizadu dae su mere de su copyright, dae s'agente suo o dae cale si siat lege."]
["5) una decraratzione firma tua, suta pena de perjuria, chi is informatziones in sa notìfica sunt acuradas e chi tenes s'autorizatzione pro aplicare is deretos de autore chi sunt istados violados; "]
['e (6) una firma fìsica o eletrònica de su mere de su deretu de autore o de una persone autorizada a agire a nùmene suo. ']
['Si non ponis totu is informatzionis de prima podit essi chi su protzedimentu ti siat tardau.']
['Contatu']
['Manda·nos una mail cun cale si siat dimanda o sugerimentu.']
How to treat lung cancer?
The treatment for lung cancer depends on several factors, including the stage of the cancer, the type of lung cancer, and the patient's overall health.
Some common treatment options include:
1. Surgery: This is often the preferred treatment for early-stage lung cancer.
The surgeon removes the tumor and a small portion of healthy tissue around it.
2. Radiation therapy: High-energy radiation is used to kill cancer cells and shrink tumors.
It can be used alone or in combination with other treatments.
3. Chemotherapy: This treatment uses drugs to kill cancer cells.
It can be given intravenously or or orally, and is often used in combination with other treatments.
4. Targeted therapy: This treatment targets specific genes or proteins that contribute to the growth and survival of cancer cells.
It is often used for advanced or metastatic lung cancer.
5. Immunotherapy: This treatment helps the immune system recognize and attack cancer cells.
It is often used for advanced or metastatic lung cancer.
6. Photodynamic therapy: This treatment uses a light-activated drug to kill cancer cells.
It is often used for early-stage lung cancer.
7. Proton therapy: This is a type of radiation therapy that uses protons instead of x-rays to deliver radiation to the tumor.
It is often used for early-stage lung cancer.
8. Clinical trials: Patients may be eligible to participate in clinical trials testing new treatments or combinations of treatments.
It is important to discuss the best treatment options with a healthcare team, as the most effective treatment plan will depend on the individual's specific situation.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Prus o mancu']
['BioMedLib impreat elaboradores automatizados (algoritmos de imparu automàticu) pro generare parigas de dimandas e rispostas.']
['Incumentzamus cun 35 milliones de publicatziones biomèdicas de PubMed/Medline. E puru, pàginas web de RefinedWeb.']
